2
项与 Live attenuated recombinant H5N1 (6-2) AA ca Recombinant vaccine(NIAID) 相关的临床试验Phase I Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine Modified H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H5N1 Infection in the Event of a Pandemic
Over the past decade, avian influenza (AI) has become a major health concern. The development of a safe and effective vaccine against H5N1 infection is important. The purpose of this study is to determine the safety of a new AI vaccine in healthy adults.
Phase 1 Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca), a Live Attenuated Virus Vaccine Candidate for the Prevention of Avian Influenza H5N1 Infection in the Event of a Pandemic
Avian influenza (AI), or bird flu, has recently become a major health concern in Asia and other parts of the world. The need for a vaccine to prevent the spread of AI among livestock and to humans is sorely needed. The purpose of this study is to test the safety of and immune response to a new AI vaccine in healthy adults.
100 项与 Live attenuated recombinant H5N1 (6-2) AA ca Recombinant vaccine(NIAID) 相关的临床结果
100 项与 Live attenuated recombinant H5N1 (6-2) AA ca Recombinant vaccine(NIAID) 相关的转化医学
100 项与 Live attenuated recombinant H5N1 (6-2) AA ca Recombinant vaccine(NIAID) 相关的专利（医药）
100 项与 Live attenuated recombinant H5N1 (6-2) AA ca Recombinant vaccine(NIAID) 相关的药物交易
